Biosimilars Uptake In EU Could Slow If Innovators Switch Pricing Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Austerity has driven biosimilars in Europe, but IMS strategist cautions that further saving could be mercurial because of ancillary costs.